Lipoprotein(a) in interventional cardiology: identifying patients at highest risk of recurrent cardiovascular events through early recognition – a case based review-Reference-Cited by-同舟云学术

Lipoprotein(a) in interventional cardiology: identifying patients at highest risk of recurrent cardiovascular events through early recognition – a case based review

Published:2024-08-02 Issue:8 Volume:22 Page:353-366
ISSN:1477-9072
Container-title:Expert Review of Cardiovascular Therapy
language:en
Short-container-title:Expert Review of Cardiovascular Therapy

Author:

Renkens Mick P. L.¹,Coerkamp Casper F.¹,Witte Lars S.¹,Sivanesan Shabiga¹,Nurmohamed Nick S.¹^ORCID,Westerterp Marit²,Serruys Patrick³,Onuma Yoshinobu³,Grundeken Maik J.¹,Kalkman Deborah N.¹,Beijk Marcel¹,Vis Marije M.¹,Henriques José P. S.¹,Delewi Ronak¹,Stroes Erik⁴,Wykrzykowska Joanna J.⁵,de Winter Robbert J.¹,Claessen Bimmer E. P. M.¹

Affiliation:

1. Department of Cardiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands

2. Department of Pediatrics, University Medical Centre Groningen, Groningen, The Netherlands

3. CORRIB Research Centre for Advanced Imaging and Core Laboratory, University of Galway, Galway, Ireland

4. Department of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands

5. Department of Cardiology, University Medical Centre, Groningen, The Netherlands

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14779072.2024.2387678

Reference64 articles.

1. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement

2. Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality

3. Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease

4. Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction

5. Association ofLPAVariants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies